China SXT Pharmaceuticals
SXTC
6 hedge funds and large institutions have $65.5K invested in China SXT Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
53% less capital invested
Capital invested by funds: $139K → $65.5K (-$73.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$26.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$13.5K |
| 3 |
Renaissance Technologies
New York
|
+$13.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$13.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$37K |
| 2 |
VF
Virtu Financial
New York
|
-$26.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Acadian Asset Management
Boston,
Massachusetts
| $28K | +$26.9K | +2 | +100% |
|
|
VF
2
Virtu Financial
New York
| $11K | -$26.9K | -2 | -67% |
|
|
3
Renaissance Technologies
New York
| $10K | +$13.5K | +1 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| $7.02K | +$13.5K | +1 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $5.1K | +$13.5K | +1 | New |
|
|
TSS
6
Two Sigma Securities
New York
| $4.4K | – | – | – |
|
|
7
Millennium Management
New York
| – | -$37K | -2 | Closed |
|
SXTC Hedge Fund Activity: Q1 2023 in Review
6 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q1 2023, worth a combined $65.5K — down 53% from $139K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SXTC positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $26.9K. The largest seller was Millennium Management, exiting entirely with an estimated $37K sold.
- 6 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q1 2023, up from 4 in Q4 2022.
- Funds reported $65.5K of China SXT Pharmaceuticals stock for Q1 2023, down 53% quarter-over-quarter.
- 3 funds opened new China SXT Pharmaceuticals positions in Q1 2023 and 1 closed out, a net change of +2 holders.
- The largest China SXT Pharmaceuticals buyer in Q1 2023 was Acadian Asset Management, an estimated $26.9K added.
- The largest China SXT Pharmaceuticals seller in Q1 2023 was Millennium Management, an estimated $37K sold.
Based on aggregated 13F filings for Q1 2023.